Zhengxi Biotechnology
Dedicated to advancing monoclonal antibody diagnostic drugs and blood tumor immunity for superior disease detection solutions
Dedicated to advancing monoclonal antibody diagnostic drugs and blood tumor immunity for superior disease detection solutions
Zhengxi Biotechnology is a biotech startup founded in 2017 and is dedicated to advancing monoclonal antibody diagnostic drugs and blood tumor immunity for superior disease detection solutions. The company focuses on R&D and production of monoclonal antibody diagnostic drugs, blood tumor immunity, and other related disease detection services. Zhengxi Biotechnology operates in the Biotechnology and Health Care industries.
The company recently secured a Series A investment on 07 October 2023, with participation from Future Invest and Huzhou Xiexing Investment Development. This round of funding is expected to bolster their efforts in innovating disease detection technologies and expanding their product line. Zhengxi Biotechnology's continued focus on cutting-edge solutions in the biotech and healthcare sectors positions it to capture significant market share and make impactful contributions to the industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | Unknown | 2 |
|
07 Oct 2023 |
No recent news or press coverage available for Zhengxi Biotechnology.
We care about your data, and we'd love to use cookies make your experience better.
